1999
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
Kantoff P, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer E, Vogelzang N. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal Of Clinical Oncology 1999, 17: 2506-13. PMID: 10561316, DOI: 10.1200/jco.1999.17.8.2506.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerTreatment failureDisease progressionPain controlSurvival durationProstate cancerResults of treatmentOverall survivalPalliative optionMore frequent responsesPatientsHydrocortisoneLife parametersNew drugsCancerMitoxantroneProgressionSurvivalDiseasePossible benefitsMenTreatmentFrequent responseFailureDuration
1998
Cancer Pain Survey Patient-Centered Issues in Control
Thomason T, McCune J, Bernard S, Winer E, Tremont S, Lindley C. Cancer Pain Survey Patient-Centered Issues in Control. Journal Of Pain And Symptom Management 1998, 15: 275-284. PMID: 9654832, DOI: 10.1016/s0885-3924(98)00016-5.Peer-Reviewed Original ResearchConceptsCancer pain controlPain controlCancer pain managementCancer-related painPain medication useHigher pain intensityCancer patients' perspectivesPain prevalenceCurrent cancer diagnosisMedication usePain intensityPain managementPatients' unwillingnessAmbulatory patientsPain assessmentPatient reluctanceSurvey patientsTreatment recommendationsAnalgesic drugsPatient's perspectiveAssociated dysfunctionEffective treatmentPainSide effectsImpaired function